

## Global smoking trends in inflammatory bowel disease

Thomas, Tom; Chandan, Joht Singh; Li, Venice Sze Wai; Lai, Cheuk Yin; Tang, Whitney; Bhala, Neeraj; Kaplan, Gilaad G; Ng, Siew C; Ghosh, Subrata

DOI:  
[10.1371/journal.pone.0221961](https://doi.org/10.1371/journal.pone.0221961)

License:  
Creative Commons: Attribution (CC BY)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Thomas, T, Chandan, JS, Li, VSW, Lai, CY, Tang, W, Bhala, N, Kaplan, GG, Ng, SC & Ghosh, S 2019, 'Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts', *PLoS ONE*, vol. 14, no. 9, e0221961. <https://doi.org/10.1371/journal.pone.0221961>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

RESEARCH ARTICLE

# Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts


Tom Thomas<sup>1,2</sup>\*, Joht Singh Chandan<sup>2</sup>, Venice Sze Wai Li<sup>3</sup>, Cheuk Yin Lai<sup>3</sup>, Whitney Tang<sup>3</sup>, Neeraj Bhala<sup>2,4</sup>, Gilaad G. Kaplan<sup>5</sup>‡, Siew C. Ng<sup>3</sup>‡, Subrata Ghosh<sup>4,6</sup>‡

**1** Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom, **2** Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, **3** Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, LKS Institute of Health Science, Chinese University of Hong Kong, Hong Kong, China, **4** University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, **5** Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada, **6** NIHR Biomedical Research Centre Birmingham, Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom

\* These authors contributed equally to this work.

‡ These authors also contributed equally to this work.

\* [tom.thomas@nhs.net](mailto:tom.thomas@nhs.net)



## OPEN ACCESS

**Citation:** Thomas T, Chandan JS, Li VSW, Lai CY, Tang W, Bhala N, et al. (2019) Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. PLoS ONE 14(9): e0221961. <https://doi.org/10.1371/journal.pone.0221961>

**Editor:** Stefanos Bonovas, Humanitas University, ITALY

**Received:** March 19, 2019

**Accepted:** August 18, 2019

**Published:** September 23, 2019

**Copyright:** © 2019 Thomas et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the manuscript and its Supplementary files.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** (IBD), Inflammatory Bowel Disease; (CD), Crohn's disease; (UC), ulcerative colitis.

## Abstract

### Background and aims

The effect of smoking on the risk of developing inflammatory bowel diseases (IBD) may be heterogeneous across ethnicity and geography. Although trends in smoking for the general population are well described, it is unknown whether these can be extrapolated to the IBD cohort. Smoking prevalence trends specific to the global IBD cohort over time have not been previously reported. This is a systematic review of smoking prevalence specific to the IBD cohort across geography.

### Methods

A systematic literature search was conducted on Medline and Embase from January 1<sup>st</sup> 1946 to April 5<sup>th</sup> 2018 to identify population-based studies assessing the prevalence of smoking at diagnosis in inception cohorts of Crohn's disease (CD) or ulcerative colitis (UC). Studies that did not report smoking data from time of diagnosis or the year of IBD diagnosis were excluded. Prevalence of smoking in IBD was stratified by geography and across time.

### Results

We identified 56 studies that were eligible for inclusion. Smoking prevalence data at diagnosis of CD and UC was collected from twenty and twenty-five countries respectively. Never-smokers in the newly diagnosed CD population in the West has increased over the last two decades, especially in the United Kingdom and Sweden; +26.6% and +11.2% respectively. Never-smokers at CD diagnosis in newly industrialised nations have decreased over the 1990s and 2000s; China (-19.36%). Never-smokers at UC diagnosis also decreased in

China; -15.4%. The former-smoker population at UC diagnosis in China is expanding; 11% (1990–2006) to 34%(2011–2013).

## Conclusion

There has been a reduction in the prevalence of smoking in the IBD cohort in the West. This is not consistent globally. Although, smoking prevalence has decreased in the general population of newly industrialised nations, this remains an important risk factor with longer term outcomes awaiting translation in both UC and CD.

## Introduction

Our group has extensively reported that inflammatory bowel diseases (IBD) have become a global challenge in the 21<sup>st</sup> century.[1–5] The rapidly accelerating incidence of both Crohn's disease (CD) and ulcerative colitis (UC) in the newly industrialized countries in the East mirrors epidemiological patterns of IBD in the West more than 75 years ago.[2] The evolving epidemiology of IBD is thought to be associated with the industrialisation of society. The rise of IBD incidence in newly industrialised nations combined with reports of comparable rates of IBD in migrant and native populations in the West[6] support the theory that environmental triggers and Western lifestyle have an integral role in the pathogenesis of IBD. [3,4]

The dichotomous relationship between smoking and the development of IBD has been the subject of intense scrutiny and is a complex interplay of genetics, immunology and environment. In the West, smoking has been consistently reported as a risk factor for developing CD and adversely affects disease course[7–9], whereas former smokers and non-smokers are at increased risk of developing UC in comparison to current smokers.[10,11] In contrast, studies in non-Western populations have been unable to replicate this association between CD and smoking.[12] The interaction between smoking and the NOD-2 gene and their effect on the risk of CD has been postulated to be specific to the 1007 fs mutation and a negative association between NOD-2 mutation and smoking could be explained by their inverse relationship.[13]

An understanding of global smoking prevalence trends specific to the IBD cohort is required as the foundation for further investigation of the heterogeneous influence of this risk factor in IBD pathogenesis and disease course across different regions. In addition, this is increasingly important in light of the identification of smoking as a key risk factor for non-response to anti-TNF agents in patients with CD.[14] However, the global prevalence of smoking associated with IBD have not been collated and reported. We conducted a systematic review to assess the prevalence of smoking in all population based IBD inception cohort studies. We examined smoking prevalence specific to individual IBD cohorts across time and geography.

## Materials and methods

### Search strategy and selection criteria

This systematic review was conducted according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.[15] A systematic literature search (S1 Table) was conducted on Medline (01 January 1946 to April 5th 2018) and Embase (01 January 1947 to April 5th 2018) for studies assessing the prevalence of smoking at diagnosis in inception IBD cohorts. All studies from our previous systematic review on IBD epidemiology[1],[5] as well as

the reference lists of all relevant articles were included. We also obtained data outside of the search strategy using expert knowledge of active studies as with the Asia-Pacific Crohn's and Colitis Epidemiologic Study Group [ACCESS]).

All stages of the systematic review were independently conducted by two teams; the first from the United Kingdom (TT and JSC) and the second from Hong Kong (SCN, VSWL and CYL). The first stage consisted of an initial screening of abstracts and titles of search results. Studies were excluded if they were not observational in design and did not report original data (i.e. review articles). Studies were considered for final inclusion in the review if their study participants consisted of a population-based inception cohort of CD and/or UC with raw numbers reported to enable the calculation of ever and/or never smoking proportion at time of IBD diagnosis. Studies could also be included if they expressed the frequency of smokers or non-smokers. A study was considered to be population-based if the sample was representative of geographical region. Smoking data had to be reported separately in CD and UC cohorts for inclusion. Studies that did not report smoking data from time of diagnosis or did not have the year of IBD diagnosis were excluded. Discrepancies between the reviewers were resolved in conjunction with GKK, SG and SCN. The flow chart for the above process is presented in [Fig 1](#).

## Data analysis


The data extracted included: author, geographical location, study period, size of CD or UC cohort, frequency of current, former and never-smokers including unknown smoking status. Study quality was ascertained using a modified version of the Newcastle-Ottawa Scale ([S2 Table](#)). The modified scale addressed aspects of quality relevant to population-based inception cohorts as well as ascertainment of smoking exposure.

We classified geographic regions according to proximity and economic similarity based upon the United Nations classification of economic region as in our previous work.[\[1\],\[5\]](#) The regions included are: North America, South America, Eastern Europe, Northern Europe, Southern Europe, Western Europe, Asia and Oceania.

Scatter plots (created using Plotly (Montreal, Canada) were used to display time trends across geography in the proportion of never and ever smokers in inception cohorts of CD ([Fig 2](#)) and UC ([Fig 3](#)) between 1980 to 2013. The earliest and latest years for which smoking data was available was 1980 and 2013 respectively. Smoking prevalence in local jurisdictions/regions were extrapolated to the entire country. In studies that reported smoking prevalence across a range of years, the median year was selected. Where studies reported former smokers, these patients were pooled with current smokers to formulate an ever-smoker category. In studies that reported only current and former category or an ever smoker category, the remainder of the population were designated as never-smokers. In UC, we sought to assess the former smoker population as this is considered the at-risk population. However, the former smoker population was also incorporated into the ever smoker population and reported for consistency. Studies with a total sample size of less than 10 subjects were excluded from these graphs. Further analysis in the form of meta-analysis or time trend analyses were not deemed appropriate due to paucity of data and heterogeneity in study design. Apart from ever smoking and never smoking data, quantitation of smoking in terms of average number of cigarettes smoked or duration of smoking were not available from the population based epidemiological data.

## Results

We identified 41 records from our previous research on IBD inception cohorts<sup>1</sup>. Our search strategy identified 3152 additional records from MEDLINE and Embase from January 1948 to April 31<sup>st</sup> 2018. [Fig 1](#) demonstrates the number of records eligible for and removed prior to




**Fig 1. Study selection.**

<https://doi.org/10.1371/journal.pone.0221961.g001>


full text review. 56 studies were eligible for final inclusion in the systematic review. These included 44 studies in CD and 46 studies in UC (Fig 1). Characteristics of all included studies are presented in Tables 1 and 2.

Smoking prevalence figures were reported for: North America (2 studies), South America (1 study), Eastern Europe (3 studies), Northern Europe (16 studies), Southern Europe (12 studies), Western Europe (4 studies), Asia (15 studies), and Oceania (3 studies). Scatter plots representing never-smoker prevalence in the CD and UC cohorts from 1980 to 2018 stratified by geographic region are presented in Figs 2 and 3 respectively. Smoking prevalence varied greatly according to geographic region. Fig 2 shows that an increasing number of the newly diagnosed CD population over the last two decades in the West particularly in the UK have never smoked. In contrast, a decrease in the proportion of never-smokers over the 1990s and 2000s is seen in newly industrialised nations such as China. Fig 3 is suggestive of significant heterogeneity in the trend of the never-smoker group in the newly diagnosed UC population in the West. Data from the United Kingdom and Sweden over the 1980s and 1990s suggest a decrease in this group whilst data from Iceland and Italy show an increase in the never-smoking proportion. Fig 3



**Fig 2. The proportion of never smokers at diagnosis in global population based inception cohorts of Crohn's disease stratified by region, country and year (1946–2018).**

<https://doi.org/10.1371/journal.pone.0221961.g002>



**Fig 3. The proportion of never smokers at diagnosis in global population based inception cohorts of ulcerative colitis stratified by region, country and year (1946–2018).**

<https://doi.org/10.1371/journal.pone.0221961.g003>



Table 1. Smoking prevalence in global population-based inception cohorts of Crohn's disease stratified by region, country and year (1946–2018).

Author	Country	Area	Year	Total CD (n)	Age Category	Age; Mean* (SD), Median <sup>#</sup> (Range)	Ever Smoker (n)	Ever Smoker (%)	Never Smoker (n)	Never Smoker (%)	Missing Data	Defined smoking groups <sup>a</sup>
<b>Asia (n = 8)</b>												
Leong 2004[56]	China	Hong Kong	1985–2001	80	all ages	33.1 (14)*	20	25	60	75	0	Yes
Lok 2007[30]	China	Hong Kong	1991–2006	27	all ages	26 (11–56)*	2	7.4	25	92.6	0	Yes
Zhao 2013[57]	China	Wuhan	2010	34	all ages	36 <sup>#</sup>	22	65	12	35	0	Yes
Zeng 2013[58]	China	Guangdong	2011–2012	17	all ages	25*	2	11.8	15	88.2	0	Yes
ACCESS Study	China	Nationwide	2011–2013	142	-	-	38	26.8	104	73.2	3.4	Yes
Yang 2014[59]	China	Daqing	2012–2013	2	all ages	39.5*	2	100	0	0	0	Yes
Zahedi 2014[60]	Iran	Kerman	2011–2012	6	all ages	33.3*	2	33.3	4	66.6	0	No
Tozun 2009[61]	Turkey	Nationwide	2001–2003	216	all ages	37.4 (12.8)*	87	40.3	129	59.7	0	Yes
<b>Eastern Europe (n = 3)</b>												
Lakatos 2013[8]	Hungary	Veszprem	1977–2001	506	all ages	31.5 (13.8)*	239	55.7	224	44.3	0	No
Lakatos 2011[28]	Hungary	Veszprem	2002–2006	163	all ages	32.5 (15.1)*	81	49.8	82	50.2	0	Yes
Gheorghe 2004[62]	Romania	Nationwide	2002–2003	85	all ages	43.9 (15.6)*	25	29.8	60	71.2	0	Yes
<b>Northern Europe (n = 16)</b>												
Ramadas 2010[63]	UK	Cardiff	1986–1991	105	all ages	30 (4–78) <sup>#</sup>	52	49	n/a	n/a	0	No
Yapp 2000[18]	UK	Cardiff	1991–1995	84	all ages	-	36	43	32	38	19	Yes
Ramadas 2010[63]	UK	Cardiff	1992–1997	99	all ages	29 (12–73) <sup>#</sup>	39	39	n/a	n/a	0	No
Garcia 2005[64]	UK	Nationwide	1995–1997	171	20–84	-	79	46.2	74	43.3	10.5	Yes
Tsironi 2004[33]	UK	Tower Hamlets	1997–2001	19	all ages	19 (10–75) <sup>#</sup>	6	31.6	13	68.4	0	No
Ramadas 2010[63]	UK	Cardiff	1998–2003	137	all ages	31 (7–84) <sup>#</sup>	57	41	n/a	n/a	0	No
Gunesh 2008[65]	UK	Cardiff	1996–2005	212	all ages	31 (8–87) <sup>#</sup>	109	51.4	93	43.9	4.7	Yes
Chhaya 2016[19]	UK	Nationwide	1989–2009	9391	all ages	-	2787	29.7	6070	64.6	5.7	Yes
Persson 1990[16]	Sweden	Stockholm County	1984–1987	152	>15 years	-	101	66.5	48	31.6	1.97	Yes
Sjoberg 2014[17]	Sweden	Uppsala	2005–2009	264	all ages	34.8 (19.4)*	81	30.7	113	42.8	26.5	Yes
Kiudelis 2012[66]	Lithuania	Kaunas	2007–2009	16	all ages	34.94 (10.4)*	6	37.5	10	62.5	0	Yes
Bjornsson 1998[36]	Iceland	Nationwide	1980–1989	75	all ages	34.4 (4–79) <sup>#</sup>	18	24	7	9.3	66.7	Yes
Bjornsson 2000[37]	Iceland	Nationwide	1990–1994	64	all ages	29.7 (9–76) <sup>#</sup>	20	31.3	27	42.1	26.6	Yes
Bjornsson 2015[67]	Iceland	Nationwide	1995–2009	279	all ages	38 (3–86) <sup>#</sup>	76	27.2	n/a	n/a	35	No
Hammer 2016[68]	Faroe Islands	Faroe Islands	1960–2014	113	all ages	41*	52	54	43	46	0	Yes
Vind 2006[35]	Denmark	Copenhagen	2003–2005	209	all ages	31 (10–85) <sup>#</sup>	108	51.7	92	44	4.3	Yes
<b>Southern Europe (n = 9)</b>												
Vucelic 1991[69]	Croatia	Zagreb	1975–1989	106	all ages	-	52	49	n/a	n/a	n/a	No
Manousos 1996b [70]	Greece	Heraklion	1990–1994	37	all ages	-	28	76	9	24	0	Yes
Franceschi 1987 [24]	Italy	Milan	1983–1984	109	all ages	-	82	75.23	17	15.6	0	Yes
Tragnone 1993[40]	Italy	Bologna	1986–1989	38	>10 years	36.6 (10–80)*	18	48	20	52	0	Yes
Ranzi 1996[25]	Italy	Crema and Cremona	1990–1994	40	all ages	-	15	39	23	61	5	Yes
Cottone 2006[71]	Italy	Casteltermine	1979–2002	29	all ages	29 (17–62) <sup>#</sup>	20	68.9	9	31	0	Yes
Fraga 1997[39]	Spain	Barcelona	1997	54	-	37 (14)*	30	55.5	24	44	0	Yes
Rodrigo 2004[27]	Spain	Oviedo	2000–2002	37	all ages	33 (15)*	17	46	n/a	n/a	n/a	No

(Continued)

Table 1. (Continued)

Author	Country	Area	Year	Total CD (n)	Age Category	Age; Mean* (SD), Median* (Range)	Ever Smoker (n)	Ever Smoker (%)	Never Smoker (n)	Never Smoker (%)	Missing Data	Defined smoking groups <sup>a</sup>
Garrido 2004[26]	Spain	Huelva	1980–2003	30	all ages	32.3 (13–42)*	10	66.7	n/a	n/a	n/a	No
<b>Western Europe (n = 4)</b>												
Abakar-Mahamat 2007[22]	France	Corsica	2002–2003	20	all ages	29 (11–58) <sup>#</sup>	7	35	13	65	0	No
Ott 2008[23]	Germany	Oberpfalz	2004–2006	168	all ages	28.9 (1–75) <sup>#</sup>	62	36.9	106	63.1	0	Yes
Van der Heide 2011 [20]	Netherlands	Leeuwarden	1996	128	≥18 years	30 (23–42) <sup>#</sup>	90	70.3	38	29.7	0	Yes
Romberg-Camps 2008[21]	Netherlands	South Limburg	1991–2002	476	all ages	34 (5–79)*	328	69	148	31	0	Yes
<b>Oceania (n = 2)</b>												
Vegh 2014[44]	Australia	Melbourne	2011	38	≥15 years	37 (17–77) <sup>#</sup>	13	34.2	20	52.6	13.2	Yes
Niewiadomski 2015 [72]	Australia	Victoria	2007–2013	146	all ages	36 (11–82) <sup>#</sup>	32	22	114	78	0	No
<b>North America (n = 1)</b>												
Edwards 2008[73]	Barbados	Nationwide	1980–2004	47	all ages	-	2	4	n/a	n/a	n/a	No
<b>South America (n = 1)</b>												
Parente 2015[74]	Brazil	Piaui	2011–2012	100	≥18 years	32.9 (13.6)*	21	21	79	79	0	No

<sup>a</sup>The study defined the current smoker and former smoker or never smoker groups. Alternatively, the authors quantified missing data.

<https://doi.org/10.1371/journal.pone.0221961.t001>

shows that the proportion of people who have never smoked at UC diagnosis in newly industrialised nations particularly China has been decreasing over the last two decades. Tables 3 and 4 displays these ranges stratified according to geographic region.

## Crohn's disease

Smoking prevalence data at diagnosis of CD was collected from twenty countries. The western world particularly Europe has demonstrated an overall increase in the prevalence of never smokers in the newly diagnosed CD cohort over the last three decades.

In Sweden (Northern Europe), the proportion of never-smokers increased from 31.6% [16] in the 1980s to 42.8% (2007) [17]. In the early 1990s, the proportion of never-smokers in the newly diagnosed CD cohort in the UK was 38%. [18] A large population-based inception cohort study (1989–2009) [19] in the UK estimated that 64.6% of newly diagnosed CD patients were never-smokers. This trend is replicated in Western Europe, Southern Europe and Eastern Europe. The proportion of never-smokers in the CD cohort in the Netherlands ranged from 29.7% [20] to 31% [21] in the 1990s however France and Germany demonstrated a never-smoker proportion of 65% [22] and 63.1% [23] in the 2000s respectively. In Italy (Southern Europe), there was a steady increase in the never-smoker population at CD diagnosis over the course of the 1980s [24] and 1990s. [25] Similarly, Spain showed consistent trends with the ever-smoker group steadily declining from 66% (1980 and 1990s) [26] to 46% (2001) [27] in the newly-diagnosed CD cohort. Similarly, in Hungary (Eastern Europe), the proportion of never smokers in the newly diagnosed CD cohort increased from 44.3% [8] to 50.2% [28] over the course of 30 years.



Table 2. Smoking prevalence in global population-based inception cohorts of ulcerative colitis stratified by region, country and year (1946–2018).

Author	Country	Area	Year	Total UC (n)	Age Range	Age: Mean* (SD), Median* (Range)	Ever Smoker (n)	Ever Smoker (%)	Former -Smoker (n)	Former -Smoker (%)	Never Smoker (n)	Never Smoker (%)	Missing Data (%)	Defined smoking groups <sup>a</sup>
Asia (n = 13)														
Chow 2009[41]	China	Hong Kong	1985–2006	172	≥15 years	37 (12–85) <sup>#</sup>	26	15.1	n/a	n/a	146	84.9	0	Yes
Lok 2008[42]	China	Hong Kong	1990–2006	73	all ages	40.6 <sup>*</sup>	15	20.6	8	11	58	79.4	0	No
Zhai 2017[75]	China	Yinchuan	2003–2012	421		42.7 <sup>#</sup>	83	19.7	3	0.7	338	80.3	0	Yes
Zhao 2013[57]	China	Wuhan	2010	97	all ages	41 <sup>#</sup>	15	16	10	10	82	85	0	Yes
ACCESS Study	China	Nationwide	2011–2013	334		-	96	28.7	63	18.9	232	69.5	1.8	Yes
Yang 2014[59]	China	Daqing	2012–2013	25	all ages	48.9 (12.5) <sup>*</sup>	9	36	5	20	16	64	0	Yes
ACCESS Study	India	Hyderabad	2011–2013	23		-	2	8.70	1	4.35	21	91	0	Yes
Zahedi 2014[60]	Iran	Kerman	2011–2012	36	all ages	39.4 <sup>*</sup>	11	30	n/a	n/a	25	70	0	No
Nakamura 1994 [76]	Japan	Nationwide	1988–1990	384	all ages	-	132	34.4	84	21.9	252	65.6	0	Yes
Radhakrishnan 1997[77]	Oman	Nationwide	1987–1994	108	all ages	36 (13–70) <sup>*</sup>	15	13.5	10	9.3	93	86.5	0	Yes
Song 2018[78]	South Korea	Seoul	1977–2014	3060	all ages	36.4 (26–48) <sup>*</sup>	1181	38.6	665	21.7	1794	58.6	2.8	Yes
Tezel 2003[79]	Turkey	Trakya	1998–2002	49	≥15 years	41 (12) <sup>*</sup>	26	53	20	40.8	23	46.9	0	Yes
Tozun 2009[61]	Turkey	Nationwide	2001–2003	661	all ages	42.6 (14.6) <sup>*</sup>	102	15.4	n/a	n/a	559	84.6	0	Yes
Eastern Europe (n = 3)														
Lakatos 2013[8]	Hungary	Veszprem	1977–2008	914	all ages	38.9 (15.9) <sup>*</sup>	297	32.5	161	17.6	617	67.5	0	Yes
Lakatos 2011[28]	Hungary	Veszprem	2002–2006	220	all ages	40.5 (17.5) <sup>*</sup>	76	34.5	46	20.9	144	65.5	0	Yes
Gheorghe 2004 [62]	Romania	Nationwide	2002–2003	163	all ages	44.2 (14.6) <sup>*</sup>	21	13.3	n/a	n/a	142	86.7	0	Yes
Northern Europe (n = 11)														
Vind 2006[35]	Denmark	Copenhagen	2003–2005	326	all ages	38 (2–95) <sup>#</sup>	128	39.3	72	22.1	147	45.1	15.6	Yes
Hammer 2016 [68]	Faroe Islands	Nationwide	1960–2014	417	all ages	41 <sup>*</sup>	204	49	121	29	213	51	0	Yes
Bjornsson 1998 [36]	Iceland	Nationwide	1980–1989	282	all ages	33.9 (11–89) <sup>#</sup>	53	18.8	33	11.7	38	13.5	67.7	Yes
Bjornsson 2000 [37]	Iceland	Nationwide	1990–1994	204	all ages	34.5 (9–84) <sup>#</sup>	54	26.5	41	20	73	35.8	37.8	Yes
Bjornsson 2015 [67]	Iceland	Nationwide	1995–2009	884	all ages	37 (3–91) <sup>#</sup>	48	5.4	n/a	n/a	n/a	n/a	51	No
Kiudelis 2012 [66]	Lithuania	Kaunas	2007–2009	87	>15 years	50 (17) <sup>*</sup>	37	42.5	25	28.7	50	57.5	0	Yes
Persson 1990[16]	Sweden	Stockholm County	1984–1987	145	15–79	-	69	47.6	26	17.9	76	52.4	0	Yes
Sjoberg 2013[34]	Sweden	Uppsala	2005–2009	526	all ages	39.2 (19.3) <sup>*</sup>	171	32.5	130	24.7	171	32.5	35	Yes
Carr 1999[31]	UK	Leicester	1991–1994	74	≥16 years	-	25	33.8	16	21.6	49	66.2	0	Yes

(Continued)

Table 2. (Continued)

Author	Country	Area	Year	Total UC (n)	Age Range	20–84	Age; Mean* (SD), Median* (Range)	Ever Smoker (n)	Former Smoker (n)	Former Smoker (%)	Never Smoker (n)	Never Smoker (%)	Missing Data (%)	Yes
Garcia 2005[32]	UK	Nationwide	1995–1997	222	all ages	20–84	-	64	28.9	27	12.2	130	58.6	12.6
Tsironi 2004[33]	UK	Tower Hamlets	1997–2001	16	all ages	20–84	28 (11–73)*	10	62.5	3	18.8	6	37.5	0
<b>Southern Europe (n = 9)</b>														
Vucelic 1991[80]	Croatia	Zagreb	1975–1989	265	all ages	all ages	-	81	30.5	51	19.2	184	69.5	0
Ladas 2005[81]	Greece	Trikala	1990–1994	66	≥10 years	all ages	-	29	44	16	24.3	37	56	0
Manousos 1996a [82]	Greece	Heraklion	1990–1994	117	all ages	all ages	-	74	63.3	60	51.3	43	36.7	0
Franceschi 1987 [24]	Italy	Milan	1983–1984	124	all ages	all ages	-	72	58.1	46	37.1	52	41.9	0
Tragnone 1993 [40]	Italy	Bologna	1986–1989	73	>10 years	all ages	44.2 (16–74)*	49	68	31	43	24	33	0
Ranzi 1996[25]	Italy	Crema and Cremona	1990–1994	82	all ages	all ages	-	45	56	32	39	35	44	2.4
Garrido 2004[26]	Spain	Huelva	1980–2003	40	all ages	all ages	44.7 (39–51)*	5	12.5	n/a	n/a	n/a	n/a	n/a
Fraga 1997[39]	Spain	Barcelona	1997	86	-	all ages	40 (15)*	41	48	18	21	45	52	0
Rodrigo 2004[27]	Spain	Oviedo	2000–2002	47	all ages	all ages	45 (20)*	19	40	n/a	n/a	n/a	n/a	n/a
<b>Western Europe (n = 4)</b>														
Abakar-Mahamat 2007[22]	France	Corsica	2002–2003	49	all ages	all ages	44 (18–80)*	11	22.5	8	16.33	38	77.6	0
Ott 2008[23]	Germany	Oberpfalz	2004–2006	105	all ages	all ages	39.5 (7–81)*	44	41.9	32	30.5	61	58.1	0
Van der Heide 2011[20]	Netherlands	Leeuwarden	1996	192	≥18 years	all ages	35 (27–50)*	107	55.8	60	31.3	85	44.3	0
Romberg-Camps 2008[21]	Netherlands	South Limburg	1991–2002	630	all ages	all ages	42 (8–84)*	403	64	277	44	227	36	0
<b>Oceania (n = 3)</b>														
Abraham 2003 [43]	Australia	Sydney	1990–1993	102	all ages	all ages	-	42	41.2	30	29.4	60	58.8	0
Vegh 2014[44]	Australia	Melbourne	2011	27	≥15 years	all ages	40 (17–87)*	11	40.7	10	37	8	29.6	n/a
Niewiadomski 2015[72]	Australia	Victoria	2007–2013	96	all ages	all ages	40 (11–87)*	22	23	17	18	74	77	0
<b>North America (n = 2)</b>														
Edwards 2008[73]	Barbados	Nationwide	1980–2004	121	all ages	all ages	-	3	2	n/a	n/a	n/a	n/a	n/a
Yamamoto-Furusho 2009[83]	Mexico	Mexico City	1987–2006	848	all ages	all ages	31.3 (12.3)*	73	8.6	73	8.6	775	91.3	0
<b>South America (n = 1)</b>														
Parente 2015[74]	Brazil	Piaui	2011–2012	152	≥18 years	all ages	36.8 (14.8)*	32	21.1	n/a	n/a	120	78.9	0

<sup>a</sup>The study defined the current smoker, former smoker or never smoker groups. Alternatively, the authors quantified missing data.

<https://doi.org/10.1371/journal.pone.0221961.t002>

Table 3. Prevalence of never-smokers in global population-based inception cohorts of Crohn's disease and ulcerative colitis stratified by range and region (1946–2018).

Region	Crohn's disease		Ulcerative colitis	
	Lowest estimate	Highest estimate	Lowest estimate	Highest estimate
North America	n/a	n/a	n/a	91.3% (n = 848) 1987–2006; Mexico City, Mexico
South America	n/a	79% (n = 100) 2011–2012; Piaui, Brazil	n/a	78.9% (n = 152) 2011–2012; Piaui, Brazil
Eastern Europe	44.3% (n = 506) 1977–2001; Veszprem, Hungary	71.20% (n = 85) 2002–2003; Nationwide, Romania	65.5% (n = 220) 2002–2006; Veszprem, Hungary	86.7% (n = 163) 2002–2003; Nationwide, Romania
Northern Europe	9.3% (n = 75) 1980–1989; Nationwide, Iceland	68.4% (n = 19) 1997–2001; Tower Hamlets London, United Kingdom	13.5% (n = 282) 1980–1989; Nationwide, Iceland	66.2% (n = 74) 1991–1994; Leicester, United Kingdom
Southern Europe	15.6% (n = 109) 1983–1984; Milan, Italy	61% (n = 40) 1990–1994; Crema and Cremona, Italy	33% (n = 73) 1986–1989; Bologna, Italy	69.5% (n = 265) 1975–1989; Zagreb, Croatia
Western Europe	29.7% (n = 128) 1996; Leeuwarden, Netherlands	65% (n = 20) 2002–2003; Corsica, France	36% (n = 630) 1991–2002; South Limburg, Netherlands	77.6% (n = 49) 2002–2003; Corsica, France
Asia	35% (n = 34) 2010; Wuhan, China	92.6% (n = 27) 1991–2006; Hong Kong, China	46.9% (n = 49) 1998–2002; Trakya, Turkey	91% (n = 23) 2011–2013; Hyderabad, India, India
Oceania	52.6% (n = 38) 2011; Melbourne, Australia	78% (n = 32) 2007–2013; Victoria, Australia	29.6% (n = 27) 2011; Melbourne, Australia	77% (n = 96) 2007–2013; Victoria, Australia

N: total cohort size; n/a: not available; Studies with n<10 have been excluded.

<https://doi.org/10.1371/journal.pone.0221961.t003>

In contrast to Europe, smoking prevalence in inception CD cohorts in Asia appears to be increasing over time. The majority of CD subjects in Asia were never-smokers. The proportion of subjects who had never smoked range from 75%[29] (Hong Kong, China;1985–2001) to 92.6%[30] (Hong Kong, China;1991–2006). However, in a more recent inception cohort from Asia from 2011–2013(ACCESS), 73.2% of CD subjects were never smokers. Nine out of 44 studies did not report former smokers. Never-smoker populations were assumed to be the remainder of the population if ever smoker data was provided.

## Ulcerative colitis

Smoking prevalence data at diagnosis of UC was collected from twenty-five countries. Smoking trends in Europe for the newly diagnosed UC cohort showed more heterogeneity than in CD. Data from the United Kingdom appear to suggest a decrease in the never-smoker proportion in the UC cohort during the 1990s; 66.2%(1993)[31] to 58.6%(1995–1997)[32] and 37.5% (1999)[33]. The former smoker population appears to have decreased in the same decade from 21.6%[31] to 18.8%[33]. Data from Sweden demonstrate reduction in the never smoker population from 52.4%(1984–1987)[16] to 32.5%(2005–2009)[34]. An increase in the proportion of former smokers at diagnosis from 17.9%(1984–1987)[16] to 24.7%(2005–2009)[34] was noted. Other Scandinavian regions such as Denmark showed only a slightly higher proportion of never smokers in their UC cohorts; 45%(2004)[35]. In contrast to the remainder of Northern Europe in the 1980s and 1990s, Iceland demonstrated an increase in the never-smoker proportion from 13.5%[36] to 35.8%[37] across this period. The percentage of former smokers at UC

**Table 4. Prevalence of ever-smokers in global population-based inception cohorts of Crohn's disease and ulcerative colitis stratified by range and region (1946–2018).**

Region	Crohn's disease		Ulcerative colitis	
	Lowest estimate	Highest estimate	Lowest estimate	Highest estimate
North America	n/a	4% (n = 47) 1980–2004; Barbados, Nationwide	n/a	8.6% (n = 848) 1987–2006; Mexico City, Mexico
South America	n/a	21% (n = 100) 2011–2012; Piaui, Brazil	n/a	21.1% (n = 152) 2011–2012; Piaui, Brazil
Eastern Europe	29.8% (n = 85) 2002–2003; Nationwide, Romania	55.7% (n = 506) 1977–2001; Veszprem, Hungary	13.3% (n = 163) 2002–2003; Nationwide, Romania	34.5% (n = 220) 2002–2006; Veszprem, Hungary
Northern Europe	24% (n = 75) 1980–1989; Nationwide, Iceland	66.5% (n = 152) 1984–1987; Stockholm County, Sweden	5.4% (n = 884) 1995–2009; Nationwide, Iceland	62.5% (n = 16) 1997–2001; Tower Hamlets, United Kingdom
Southern Europe	39% (n = 40) 1990–1994; Crema and Cremona, Italy	76% (n = 37) 1990–1994; Heraklion, Greece	12.5% (n = 40) 1980–2003; Huelva, Spain	68% (n = 73) 1986–1989; Barcelona, Spain
Western Europe	35% (n = 20) 2002–2003; Corsica, France	70.3% (n = 128) 1996; Leeuwarden, Netherlands	22.5% (n = 49) 2002–2003; Corsica, France	64% (n = 630) 1991–2002; South Limburg, Netherlands
Asia	7.4% (n = 27) 1991–2006; Hong Kong, China	65% (n = 34) 2010; Wuhan, Turkey	8.70% (n = 23) 2012; Hyderabad, India	53% (n = 49) 1998–2002; Trakya, Turkey
Oceania	22% (n = 146) 2007–2013; Victoria, Australia	34.2% (n = 38) 2011; Melbourne, Australia	23% (n = 96) 2007–2013; Victoria, Australia	41.2% (n = 102) 1990–1993; (Sydney, Australia)

N: total cohort size; n/a: not available; Studies with n<10 have been excluded.

<https://doi.org/10.1371/journal.pone.0221961.t004>

diagnosis also rose from 11.7% to 20% across those two decades. These results co-relate with a decrease in the ever-smoker proportion down to 48%[38] in the 21<sup>st</sup> century.

In Southern Europe, Spain demonstrated an increase in their ever-smoker proportion from 12.5%[26] in the 1980s and 1990s to 48%[39] in the 2000s. In Italy, the never-smoker proportion varied by geographic region; 42% (Milan; early 1980s)[24] to 33% (Bologna; late 1980s) [40] and 44% (Crema and Cremona; early 1990s)[25]. Former-smoker proportions were similarly varied across these regions and time periods: 37.1%, 43% and 39% respectively. In Eastern Europe, Veszprem (Hungary) demonstrated a reduction in the never-smoker population in the UC cohort; 67.5%(1977–2008)[8] to 65.5%(2002–2006)[28]. The former smoker population in the newly diagnosed UC cohort during those periods were 17.6% and 20.9% respectively. In contrast to the rest of Europe, never-smoker proportions increased over the late 1990s and early 2000s in Western Europe from 44.3%[20] (Netherlands; 1996) to 77.55% (France; 2003)[22] and 58.09%(Germany;2005)[23].

The proportion of newly diagnosed UC subjects who have never smoked has decreased in China over the last two decades. The proportion who had never smoked were 84.9%[41] in China in the late 1990s. By 2012 these figures had decreased to 69.5% (ACCESS Cohort;2011–2013). The proportion of former smoker patients in the newly diagnosed UC cohort in China appears to be increasing from 11%(1990–2006)[42] to 34% (Hong Kong ACCESS cohort).

Data from major cities in Australia suggest that the proportion of never-smokers in the newly diagnosed UC cohort has increased from 58.8%(Sydney;1992)[43] to 77%(Victoria; 2007–2013)[44]. The former smoker proportion of patients at diagnosis also decreased from

29.4% to 18% across the same regions and time periods respectively. The impact of missing smoking data regarding the participants vary due to heterogeneity in reporting. Four out of the 46 studies included for UC did not report former smokers at diagnosis. Never-smoker populations were assumed to be the remainder of the population if ever smoker data was provided.

## Discussion

We present a comprehensive review of smoking trends over time in inception IBD cohorts worldwide. In the West, the proportion of newly diagnosed CD subjects who have never smoked has increased over time. The proportion of newly diagnosed UC subjects who have never smoked has declined in the 1980s and 1990s in Europe although an increase was noted in Western Europe from the late 1990s. In contrast, the proportion of subjects who have never smoked at IBD diagnosis has decreased in Asia, particularly in China. Thus, we demonstrate that trends in smoking prevalence specific to the IBD cohort do not mirror global trends in smoking discerned from the general population.[45]

The incidence of IBD in newly industrialised countries is accelerating whilst the incidence of IBD is stabilising in the West.[1] The effect of smoking on the incidence of IBD across the globe likely varies due to heterogeneity in genetic susceptibility and the presence of other risk factors. Public health measures in the 1980s and 1990s led to a reduction of smoking prevalence in the general population in many Western countries.[46] The higher proportion of never smokers at diagnosis of CD over time may be explained by adolescents who decided not to smoke in the 1990s. This could have potentially contributed to the stabilization, and in certain regions decrease, in the incidence of adult-onset CD in some Western countries. This ecological trend could also explain the decrease in the former smoker population in the UK over the 1990s and could have contributed to the recent stabilisation of UC incidence.[1]

In contrast, we are at the infancy of the IBD 'epidemic' in newly industrialized countries in Asia, especially in areas of high smoking prevalence[46]; hence ever-smoker trends at IBD diagnosis are on the increase. The rapid expansion of the former smoker population at UC diagnosis in China is suggestive of a rapid expansion of the at-risk population. The Global Burden of Disease Study 2015 identified China as one of the leading countries in the world for the total number of smokers.[46] In line with the Lopez model[47], these newly industrialised nations are rapidly moving towards Stage IV where smoking prevalence in the general population will decrease as societal attitudes shift and government anti-smoking policy becomes comprehensive. This could potentially foreshadow a protracted course of high UC incidence in comparison to CD. Similar to the West, we hypothesise that a 'lag effect' can be expected in future epidemiological studies particularly in CD based in newly industrialised nations. However, due to the complex interplay between genetics and environment in the development of IBD, this effect may not be as pronounced as in the West[12] although in contrast to CD, there is some evidence to suggest that the role of smoking in UC is uniform across the East and West.[12,48,49]

The concurrent decrease of the never-smoker population in both CD and UC cohorts in newly industrialised nations is potentially suggestive of significant heterogeneity in the interaction between smoking and the process of IBD development across geographic regions. Even in the West, the incidence of CD had been high in relatively low smoking prevalence populations i.e. Israeli Jews[50], Canada, and Sweden. Multiple studies[12],[29],[51] in the Asia-Pacific region have demonstrated that active smoking does not confer an increased risk of CD in this population as it does in the West. The relative absence of the NOD-2 mutation in CD cases in Japan suggests that the role of smoking in IBD is subject to underlying genetic heterogeneity.[52] Environmental factors such as air pollution[53], diet and a Western lifestyle as demonstrated in migrant sub-populations[6] as well as evolving early life feeding patterns and

improved hygiene as part of socioeconomic development[12] could be more potent mediators of IBD development.[54,55]

Our study has several limitations predominantly due to lack of available data. We were unable to perform a meta-analysis or ecological trend analysis due to study heterogeneity. Small sample sizes in some studies have also increased the risk of imprecise estimates for smoking prevalence. A paucity of gender-specific, age-category specific smoking prevalence data, data relating to quantification of smoking habits or breakdown of rural vs. urban data in the IBD cohort did not allow for further sub-group analysis. Although, it is possible studies that included children and adolescents would have a higher prevalence of never-smokers, summary statistics from included studies suggest this is not the case. The exposure to smoking was reported inconsistently; some studies reported current and former smokers whilst others reported ever and never smokers. Twenty three out of ninety-five included cohorts reported missing smoking data on participants (Tables 1 and 2). No data was available regarding second-hand smoking exposure. Due to differing study periods and the generalisation of regions to represent countries, smoking data was not fully homogenous. The inequalities in healthcare access across the globe can also affect data collection and reporting. In addition, we acknowledge that the attributable risk of smoking on IBD is low (i.e. most IBD patients do not have a history of smoking [current or former] prior to their diagnosis), however it remains an important risk mediator in the development of IBD.

Despite these limitations, this study provides a comprehensive overview of the prevalence of smoking in the global IBD cohort across time and geography. The proportion of never-smokers in IBD cohorts from newly industrialised countries appears to be decreasing over time in contrast to the IBD cohorts in the West. In light of our previous work and this study, it appears that IBD epidemiological patterns globally can be modelled along geographical and development lines within a context of genetic heterogeneity and environmental ecological exposures. It remains of clinical importance for medical practitioners to record information and act on smoking status for patients with IBD regardless of geography and ethnicity, especially in light of data suggesting smoking confers an adverse disease course in CD and is a risk factor in non-response to anti-TNF therapy.[14] Large-scale prospective inception cohorts assessing the associations of smoking for both UC and CD in Eastern and Western populations will add to the available data.

This is the first systematic review to assess trends in the prevalence of smoking in the IBD cohort worldwide. It provides a foundation for future work assessing the prevalence of this important risk mediator in a global setting as well as highlighting some of the challenges surrounding this data. A deeper understanding of IBD aetiology in relation to diet and other environmental factors across geographic regions and ethnicities is urgently required in order to formulate strategies to slow the global increase in the incidence of IBD.

## Supporting information

**S1 Table. Detailed MEDLINE and EMBASE search strategy for article selection (1 January 1947 to April 5 2018).**

(DOCX)

**S2 Table. Quality assessment of manuscripts (modified Newcastle Ottawa scale).**

(DOCX)

## Acknowledgments

SG is supported by the NIHR Biomedical Research Centre, Birmingham.



## Author Contributions

**Conceptualization:** Tom Thomas, Joht Singh Chandan, Gilaad G. Kaplan, Siew C. Ng, Subrata Ghosh.

**Data curation:** Tom Thomas, Joht Singh Chandan, Whitney Tang, Gilaad G. Kaplan.

**Formal analysis:** Tom Thomas, Joht Singh Chandan, Venice Sze Wai Li, Subrata Ghosh.

**Investigation:** Tom Thomas, Joht Singh Chandan.

**Methodology:** Tom Thomas, Joht Singh Chandan, Venice Sze Wai Li, Cheuk Yin Lai, Neeraj Bhala, Siew C. Ng.

**Project administration:** Tom Thomas, Joht Singh Chandan.

**Resources:** Tom Thomas, Joht Singh Chandan, Subrata Ghosh.

**Software:** Tom Thomas, Joht Singh Chandan.

**Supervision:** Neeraj Bhala, Gilaad G. Kaplan, Siew C. Ng, Subrata Ghosh.

**Validation:** Tom Thomas, Joht Singh Chandan, Gilaad G. Kaplan, Siew C. Ng, Subrata Ghosh.

**Visualization:** Tom Thomas, Joht Singh Chandan, Venice Sze Wai Li, Cheuk Yin Lai.

**Writing – original draft:** Tom Thomas.

**Writing – review & editing:** Tom Thomas, Joht Singh Chandan, Venice Sze Wai Li, Cheuk Yin Lai, Whitney Tang, Neeraj Bhala, Gilaad G. Kaplan, Siew C. Ng, Subrata Ghosh.

## References

1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* (London, England) [Internet]. 2018 Dec 23 [cited 2018 Apr 15]; 390(10114):2769–78. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29050646>
2. Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* [Internet]. 2017 Jan [cited 2018 Jul 21]; 152(2):313–321.e2. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27793607>
3. Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. *Lancet Gastroenterol Hepatol* [Internet]. 2016 Dec [cited 2018 Aug 21]; 1(4):307–16. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28404201> [https://doi.org/10.1016/S2468-1253\(16\)30077-2](https://doi.org/10.1016/S2468-1253(16)30077-2) PMID: 28404201
4. Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol* [Internet]. 2015 Dec 1 [cited 2018 Aug 21]; 12(12):720–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26323879> <https://doi.org/10.1038/nrgastro.2015.150> PMID: 26323879
5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. *Gastroenterology* [Internet]. 2012 Jan [cited 2017 Sep 12]; 142(1):46–54.e42. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22001864>
6. Probert CSJ, Jayanthi V, Pinder D, Wicks AC, Mayberry JF, Probert J, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire Hindus and Sikhs have a significantly higher incidence of UC than Europeans in Leicestershire. *Gut* [Internet]. 1992 [cited 2018 Jul 18]; 33:687–93. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1379303/pdf/gut00572-0137.pdf> <https://doi.org/10.1136/gut.33.5.687> PMID: 1307684
7. Lawrance IC, Murray K, Batman B, Geary RB, Grafton R, Krishnaprasad K, et al. Crohn's disease and smoking: Is it ever too late to quit? *J Crohn's Colitis* [Internet]. 2013 Dec 15 [cited 2018 Jul 21]; 7(12):e665–71. Available from: <https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1016/j.crohns.2013.05.007>
8. Lakatos PL, Vegh Z, Lovasz BD, David G, Pandur T, Erdelyi Z, et al. Is Current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. *Inflamm Bowel Dis*. 2013; 19(4):1010–7.

9. Nunes T, Etchevers MJ, Domènech E, García-Sánchez V, Ber Y, Peñalva M, et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. *Aliment Pharmacol Ther* [Internet]. 2013 Oct [cited 2018 Jul 21]; 38(7):752–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23980933> <https://doi.org/10.1111/apt.12440> PMID: 23980933
10. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci* [Internet]. 1989 Dec [cited 2018 Jul 17]; 34(12):1841–54. Available from: <http://link.springer.com/10.1007/BF01536701> <https://doi.org/10.1007/bf01536701> PMID: 2598752
11. Mahid SS, Minor KS, Soto RE, Hornung CA, Galanduk S. Smoking and Inflammatory Bowel Disease: A Meta-analysis. *Mayo Clin Proc* [Internet]. 2006 Nov [cited 2018 Jul 17]; 81(11):1462–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17120402> <https://doi.org/10.4065/81.11.1462> PMID: 17120402
12. Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. *Gut* [Internet]. 2015 Jul [cited 2018 May 21]; 64(7):1063–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25217388> <https://doi.org/10.1136/gutjnl-2014-307410> PMID: 25217388
13. Kuenzig ME, Yim J, Coward S, Eksteen B, Seow CH, Barnabe C, et al. The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. *EBioMedicine* [Internet]. 2017 Jul [cited 2017 Sep 12]; 21:188–96. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S2352396417302475> <https://doi.org/10.1016/j.ebiom.2017.06.012> PMID: 28668336
14. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multi-centre, cohort study. *lancet Gastroenterol Hepatol*. 2019 May; 4(5):341–53. [https://doi.org/10.1016/S2468-1253\(19\)30012-3](https://doi.org/10.1016/S2468-1253(19)30012-3) PMID: 30824404
15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* [Internet]. 2000 Apr 19 [cited 2018 Jul 22]; 283(15):2008–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10789670> <https://doi.org/10.1001/jama.283.15.2008> PMID: 10789670
16. Persson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke—a case-control study. *Gut* [Internet]. 1990; 31(12):1377–81. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1378760&tool=pmcentrez&rendertype=abstract%5Cnhttp://gut.bmj.com/cgi/doi/10.1136/gut.31.12.1377> <https://doi.org/10.1136/gut.31.12.1377> PMID: 2265777
17. Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekborn A, et al. Incidence and clinical course of Crohn's disease during the first year—Results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005–2009. *J Crohn's Colitis* [Internet]. 2014; 8(3):215–22. Available from: <https://doi.org/10.1016/j.crohns.2013.08.009>
18. Yapp TR, Stenson R, Thomas GA, Lawrie BW, Williams GT HB. Crohn's disease incidence in Cardiff from 1930: an update for 1991–1995.pdf. *Eur J Gastroenterol Hepatol* [Internet]. 2000; 12(8). Available from: [https://journals.lww.com/eurojgh/Abstract/2000/12080/Crohn\\_s\\_disease\\_incidence\\_in\\_Cardiff\\_from\\_1930\\_an.10.aspx](https://journals.lww.com/eurojgh/Abstract/2000/12080/Crohn_s_disease_incidence_in_Cardiff_from_1930_an.10.aspx)
19. Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, et al. Emerging trends and risk factors for perianal surgery in Crohn's disease. *Eur J Gastroenterol Hepatol* [Internet]. 2016 Aug [cited 2018 Apr 11]; 28(8):890–5. Available from: <https://insights.ovid.com/crossref?an=00042737-201608000-00006> <https://doi.org/10.1097/MEG.0000000000000651> PMID: 27128719
20. van der Heide F, Wassenaar M, van der Linde K, Spoelstra P, Kleibeuker JH, Dijkstra G. Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospital. *Eur J Gastroenterol Hepatol* [Internet]. 2011; 23(3):255–61. Available from: <https://insights.ovid.com/crossref?an=00042737-201103000-00010> <https://doi.org/10.1097/MEG.0b013e3283435233> PMID: 21191306
21. Romberg-Camps MJL, Hesselink-van de Kruijs MAM, Schouten LJ, Dagnelie PC, Limonard CB, Kester ADM, et al. Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991–2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms. *J Crohn's Colitis* [Internet]. 2009; 3(2):115–24. Available from: <https://doi.org/10.1016/j.crohns.2008.12.002>
22. Abakar-Mahamat A, Filippi J, Pradier C, Dozol A, Hébuterne X. Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. *Gastroenterol Clin Biol*. 2007; 31(12):1098–103. PMID: 18176365
23. Ott C, Obermeier F, Thielers S, Kempner D, Bauer A, Schölmerich J, et al. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. *Eur J Gastroenterol Hepatol* [Internet]. 2008; 20(9):917–23. Available from: <https://insights.ovid.com/crossref?an=00042737-200809000-00016> <https://doi.org/10.1097/MEG.0b013e3282f97b33> PMID: 18794607

24. Franceschi S, Panza E, Vecchia C La, Parazzini F, Decarli A, Porro GB. Nonspecific inflammatory bowel disease and smoking. *Am J Epidemiol*. 1987; 125(3):445–52. <https://doi.org/10.1093/oxfordjournals.aje.a114550> PMID: 3812450
25. Ranzi T, Bodini P, Zambelli A, Politi P, Lupinacci G, Campanini MC, et al. Epidemiological aspects of inflammatory bowel disease in a north Italian population: a 4-year prospective study. *Eur J Gastroenterol Hepatol* [Internet]. 1996 Jul [cited 2018 Aug 4]; 8(7):657–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8853254> PMID: 8853254
26. Garrido a, Martínez MJ, Ortega J a, Lobato a, Rodríguez MJ, Guerrero FJ. Epidemiology of chronic inflammatory bowel disease in the Northern area of Huelva. *Rev Esp Enferm Dig* [Internet]. 2004; 96(10):687–91; 691–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15537375> PMID: 15537375
27. Rodrigo L, Riestra S, Nino P, Cadahia V, Tojo R, Fuentes D, et al. A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain). *Rev Esp Enferm Dig*. 2004; 96(5):296–305. PMID: 15180441
28. Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. *Inflamm Bowel Dis*. 2011; 17(12):2558–65. <https://doi.org/10.1002/ibd.21607> PMID: 22072315
29. Leong RWL, Lau JY, Sung JY. The epidemiology and phenotype of Crohn's disease in the Chinese population. *Inflamm Bowel Dis* [Internet]. 2004 Sep [cited 2018 Jul 18]; 10(5):646–51. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15472528> <https://doi.org/10.1097/00054725-200409000-00022> PMID: 15472528
30. Lok KH, Hung HG, Ng CH, Li KK, Li KF, Szeto ML. The epidemiology and clinical characteristics of Crohn's disease in the Hong Kong Chinese population: experiences from a regional hospital. *Hong Kong Med J* [Internet]. 2007; 13(6):436–41. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18057431> PMID: 18057431
31. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: A three-year prospective study among Europeans and first- and second-generation South Asians in Leicester (1991–1994). *Am J Gastroenterol*. 1999; 94(10):2918–22. <https://doi.org/10.1111/j.1572-0241.1999.01438.x> PMID: 10520845
32. García-Fontana B, Morales-Santana S, Longobardo V, Reyes-García R, Rozas-Moreno P, García-Salcedo J, et al. Relationship between Proinflammatory and Antioxidant Proteins with the Severity of Cardiovascular Disease in Type 2 Diabetes Mellitus. *Int J Mol Sci* [Internet]. 2015 Apr 27 [cited 2016 Dec 27]; 16(5):9469–83. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25923078> <https://doi.org/10.3390/ijms16059469> PMID: 25923078
33. Tsironi E, Feakins RM, Roberts CSJ, Rampton DS. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. *Am J Gastroenterol*. 2004; 99(9):1749–55. <https://doi.org/10.1111/j.1572-0241.2004.30445.x> PMID: 15330914
34. Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbohm A, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005–2009—Results from the IBD Cohort of the Uppsala Region (ICURE). *J Crohn's Colitis* [Internet]. 2013; 7(9):e351–7. Available from: <https://doi.org/10.1016/j.crohns.2013.02.006>
35. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjær M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: A population-based study from the Danish Crohn colitis database. *Am J Gastroenterol*. 2006; 101(6):1274–82. <https://doi.org/10.1111/j.1572-0241.2006.00552.x> PMID: 16771949
36. BJÖRNSSON S., JOHANNSSON J. H., JHJEO E. Inflammatory Bowel Disease in Iceland, 1980–89: A Retrospective Nationwide Epidemiologic Study. *Scand J Gastroenterol* [Internet]. 1998 Jan 8 [cited 2018 Aug 3]; 33(1):71–7. Available from: <http://www.tandfonline.com/doi/full/10.1080/00365529850166239> <https://doi.org/10.1080/00365529850166239> PMID: 9489911
37. JH BS and J. Inflammatory bowel disease in Iceland, 1990–1994: a prospective, nationwide, epidemiological study.pdf. *Eur J Gastroenterol Hepatol*. 2000; 12:31–8. <https://doi.org/10.1097/00042737-200012010-00007> PMID: 10656207
38. Björnsson S, Tryggvason FP, Jónasson JG, Cariglia N, Örvar K, Kristjánsdóttir S, et al. Incidence of inflammatory bowel disease in Iceland 1995–2009. A nationwide population-based study. *Scand J Gastroenterol*. 2015; 50(11):1368–75. <https://doi.org/10.3109/00365521.2015.1047792> PMID: 25979112
39. Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B MJ. Effects of smoking on the presentation and clinical course of inflammatory bowel disease.pdf. *Eur J Gastroenterol Hepatol*. 1997; 9(7):683–7. <https://doi.org/10.1097/00042737-199707000-00007> PMID: 9262977
40. Tragnone A, Hanau C, Bazzocchi G, Lanfranchi GA. Epidemiological characteristics of inflammatory bowel disease in Bologna, Italy—incidence and risk factors. *Digestion* [Internet]. 1993; 54(3):183–8. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8359562%5Cnhhttp://openurl.ac.uk/athens:lee/?sid=OVID:medline&id=pmid:8359562&id=>

- doi:&issn=0012-2823&isbn=&volume=54&issue=3&page=183&pages=183-8&date=1993&title=Digestion&title https://doi.org/10.1159/000201036 PMID: 8359562
41. Chow DKL, Leong RWL, Tsoi KKF, Ng SSM, Leung W, Wu JCY, et al. Long-term Follow-up of Ulcerative Colitis in the Chinese Population. *Am J Gastroenterol* [Internet]. 2009; 104(3):647–54. Available from: <http://www.nature.com/doi/10.1038/ajg.2008.74> https://doi.org/10.1038/ajg.2008.74 PMID: 19262521
  42. Lok K-H, Hung H-G, Ng C-H, Kwong KC, Yip W-M, Lau S-F, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: Experience from a single center in Hong Kong. *J Gastroenterol Hepatol* [Internet]. 2008; 23(3):406–10. Available from: <http://doi.wiley.com/10.1111/j.1440-1746.2007.05079.x> https://doi.org/10.1111/j.1440-1746.2007.05079.x PMID: 17623033
  43. Abraham N, Selby W, Lazarus R, Solomon M. Is smoking an indirect risk factor for the development of ulcerative colitis? An age- and sex-matched case-control study. *J Gastroenterol Hepatol*. 2003; 18(2):139–46. https://doi.org/10.1046/j.1440-1746.2003.02953.x PMID: 12542596
  44. Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-Epi-Com inception cohort. *J Crohn's Colitis*. 2014; 8(11):1506–15.
  45. Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Hassen Abate K, et al. Articles Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* [Internet]. 2017 [cited 2018 Jul 17]; 389:1885–906. Available from: [https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(17\)30819-X.pdf](https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30819-X.pdf) https://doi.org/10.1016/S0140-6736(17)30819-X
  46. Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* [Internet]. 2017 May [cited 2017 Sep 12]; 389(10082):1885–906. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S014067361730819X> https://doi.org/10.1016/S0140-6736(17)30819-X PMID: 28390697
  47. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. *Tob Control* [Internet]. 1994 Sep 1 [cited 2018 Aug 25]; 3(3):242–7. Available from: <http://tobaccocontrol.bmj.com/cgi/doi/10.1136/tc.3.3.242>
  48. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. A case-control study of ulcerative colitis in relation to dietary and other factors in Japan. *J Gastroenterol* [Internet]. 1995 Nov [cited 2018 Jul 18];30 Suppl 8:9–12. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8563901>
  49. Jiang L, Xia B, Li J, Ye M, Deng C, Ding Y, et al. Risk Factors for Ulcerative Colitis in a Chinese Population. *J Clin Gastroenterol* [Internet]. 2007 Mar [cited 2018 Jul 18]; 41(3):280–4. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17426467> https://doi.org/10.1097/O1.mcg.0000225644.75651.f1 PMID: 17426467
  50. Reif S, Klein I, Arber N, Gilat T. Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. *Gastroenterology* [Internet]. 1995 Jun [cited 2018 Jul 17]; 108(6):1683–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7768372> https://doi.org/10.1016/0016-5085(95)90129-9 PMID: 7768372
  51. Prideaux L, Kamm MA, De Cruz P, Williams J, Bell SJ, Connell WR, et al. Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. *J Gastroenterol Hepatol* [Internet]. 2012 May [cited 2018 Jul 18]; 27(5):919–27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22098103> https://doi.org/10.1111/j.1440-1746.2011.06984.x PMID: 22098103
  52. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. *Gastroenterology* [Internet]. 2002 Jul [cited 2018 Jul 18]; 123(1):86–91. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12105836> https://doi.org/10.1053/gast.2002.34155 PMID: 12105836
  53. Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. *Am J Gastroenterol* [Internet]. 2010 Nov [cited 2018 Jul 18]; 105(11):2412–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20588264> https://doi.org/10.1038/ajg.2010.252 PMID: 20588264
  54. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. *Am J Clin Nutr* [Internet]. 1996 May 1 [cited 2018 Jul 18]; 63(5):741–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8615358> https://doi.org/10.1093/ajcn/63.5.741 PMID: 8615358
  55. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. *Inflamm Bowel Dis* [Internet]. 2005



- Feb [cited 2018 Jul 18]; 11(2):154–63. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15677909> <https://doi.org/10.1097/00054725-200502000-00009> PMID: 15677909
56. R.W.L. L, J.Y. L, Leong RWL, Lau JY, Sung JJY. The epidemiology and phenotype of Crohn's disease in the Chinese population. *Inflamm Bowel Dis* [Internet]. 2004; 10(5):646–51. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=15472528%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=2004409340> <https://doi.org/10.1097/00054725-200409000-00022> PMID: 15472528
  57. Zhao J, Ng SC, Lei Y, Yi F, Li J, Yu L, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: The emergence of “western” disease. *Inflamm Bowel Dis*. 2013; 19(9):1839–45. <https://doi.org/10.1097/MIB.0b013e31828a6551> PMID: 23669403
  58. Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study. *J Gastroenterol Hepatol* [Internet]. 2013; 28(7):1148–53. Available from: <http://doi.wiley.com/10.1111/jgh.12164> <https://doi.org/10.1111/jgh.12164> PMID: 23432198
  59. Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao W, et al. The incidence of inflammatory bowel disease in Northern China: A prospective population-based study. *PLoS One*. 2014; 9(7):5–10.
  60. Zahedi MJ, Darvish Moghadam S, Hayat Bakhsh Abbasi M, Dehghani M, Shafiei Pour S, Zydabady Nejad H, et al. The incidence rate of inflammatory bowel disease in an urban area of Iran: a developing country. *Middle East J Dig Dis* [Internet]. 2014; 6(1):32–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24829703%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4005476> PMID: 24829703
  61. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, et al. Clinical characteristics of inflammatory bowel disease in Turkey: A multicenter epidemiologic survey. *J Clin Gastroenterol*. 2009; 43(1):51–7. <https://doi.org/10.1097/MCG.0b013e3181574636> PMID: 18724251
  62. Gheorghe C, Pascu O, Gheorghe L, Iacob R, Dumitru E, Tantau M, et al. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: A multicentre study. *Eur J Gastroenterol Hepatol*. 2004; 16(11):1153–9. <https://doi.org/10.1097/00042737-200411000-00012> PMID: 15489575
  63. Ramadas A V., Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. *Gut* [Internet]. 2010 Sep 1 [cited 2018 Apr 15]; 59(9):1200–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20650924> <https://doi.org/10.1136/gut.2009.202101> PMID: 20650924
  64. GARCIA RODRIGUEZ LA, GONZALEZ-PEREZ A, JOHANSSON S, WALLANDER M-A. Risk factors for inflammatory bowel disease in the general population. *Aliment Pharmacol Ther* [Internet]. 2005; 22(4):309–15. Available from: <http://doi.wiley.com/10.1111/j.1365-2036.2005.02564.x> <https://doi.org/10.1111/j.1365-2036.2005.02564.x> PMID: 16097997
  65. Gunesh S, Thomas GAO, Williams GT, Roberts A, Hawthorne AB. The incidence of Crohn's disease in Cardiff over the last 75 years: An update for 1996–2005. *Aliment Pharmacol Ther*. 2008; 27(3):211–9. <https://doi.org/10.1111/j.1365-2036.2007.03576.x> PMID: 18005244
  66. Kiudelis G, Jonaitis L, Adamonis K, Žvirbliene A, Tamelis A, Kregždys R, et al. Incidence of inflammatory bowel disease in Kaunas region, Lithuania. *Med*. 2012; 48(8):431–5.
  67. Björnsson S, Tryggvason F, Jónasson JG, Cariglia N, Örvær K, Kristjánssdóttir S, et al. Incidence of inflammatory bowel disease in Iceland 1995–2009. A nationwide population-based study. *Scand J Gastroenterol* [Internet]. 2015 Nov 2 [cited 2018 Aug 3]; 50(11):1368–75. Available from: <http://www.tandfonline.com/doi/full/10.3109/00365521.2015.1047792> <https://doi.org/10.3109/00365521.2015.1047792> PMID: 25979112
  68. Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The Faroese IBD study: Incidence of inflammatory bowel diseases across 54 years of population-based data. *J Crohn's Colitis*. 2016; 10(8):934–42.
  69. Vucelic B\*, Korac B, Sentic M, Milicic D HN, Juresa V BJ. Epidemiology of Crohn's Disease in Zagreb, Yugoslavia. *Int J Epidemiol*. 2018; 20(1):216–20.
  70. Manousos ON, Koutroubakis I, Potamianos S, Roussomoustakaki M, Gourtsoyiannis N, Vlachonikolis IG. A prospective epidemiologic study of Crohn's disease in Heraklion, Crete: Incidence over a 5-year period. *Scand J Gastroenterol*. 1996; 31(6):599–603. <https://doi.org/10.3109/00365529609009134> PMID: 8789900
  71. Cottone M, Renda MC, Mattaliano A, Oliva L, Fries W, Criscuoli V, et al. Incidence of Crohn's disease and CARD15 mutation in a small township in Sicily. *Eur J Epidemiol*. 2006; 21(12):887–92. <https://doi.org/10.1007/s10654-006-9054-5> PMID: 17160430
  72. Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, et al. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity. *J Gastroenterol Hepatol*. 2015; 30(9):1346–53. <https://doi.org/10.1111/jgh.12967> PMID: 25867770

73. Edwards CN, Griffith SG, Hennis AJ, Hambleton IR. Inflammatory bowel disease: Incidence, prevalence, and disease characteristics in Barbados, West Indies. *Inflamm Bowel Dis*. 2008; 14(10):1419–24. <https://doi.org/10.1002/ibd.20495> PMID: 18484668
74. Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA, Da Silva RM, et al. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. *World J Gastroenterol*. 2015; 21(4):1197–206. <https://doi.org/10.3748/wjg.v21.i4.1197> PMID: 25632193
75. Zhai H, Huang W, Liu A, Li Q, Hao Q, Ma L, et al. Current smoking improves ulcerative colitis patients' disease behaviour in the northwest of China. *Gastroenterol Rev* [Internet]. 2017; 4(4):286–90. Available from: <https://www.termedia.pl/doi/10.5114/pg.2017.72104>
76. Nakamura Y, Labarthe DR. A case-control study of ulcerative colitis with relation to smoking habits and alcohol consumption in Japan. *Am J Epidemiol*. 1994; 140(10):902–11. <https://doi.org/10.1093/oxfordjournals.aje.a117178> PMID: 7977277
77. Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK MA. Ulcerative colitis in Oman: A prospective study of incidence and disease pattern from 1987 to 1994. *Diges*. 1997; 58:266–70.
78. Song EM, Lee H-S, Park SH, Kim GU, Seo MS, Hwang SW, et al. Clinical Characteristics and Long-term Prognosis of Elderly-onset Ulcerative Colitis. *J Gastroenterol Hepatol* [Internet]. 2017; Available from: <http://doi.wiley.com/10.1111/jgh.13826>
79. Tezel A, Dökmeci G, Eskiocak M, Ümit H, Soylu AR. Epidemiological features of ulcerative colitis in Trabzon, Turkey. *J Int Med Res*. 2003; 31(2):141–8. <https://doi.org/10.1177/147323000303100211> PMID: 12760318
80. Vuceljć B, Korać B, Sentić M, Milličić D, Hadžić N, Jureša V, et al. Ulcerative colitis in Zagreb, Yugoslavia: Incidence and prevalence 1980–1989. *Int J Epidemiol*. 1991; 20(4):1043–7. <https://doi.org/10.1093/ije/20.4.1043> PMID: 1800402
81. Ladas SD, Mallas E, Giorgiotis K, Karamanolis G, Trigonis D, Markadas A, et al. Incidence of ulcerative colitis in Central Greece: A prospective study. *World J Gastroenterol*. 2005; 11(12):1785–7. <https://doi.org/10.3748/wjg.v11.i12.1785> PMID: 15793864
82. Manousos ON, Giannadaki E, Mouzas IA, Tzardi M, Koutroubakis I, Skordilis P, et al. Ulcerative colitis is as common in Crete as in northern Europe: a 5-year prospective study. *Eur J Gastroenterol Hepatol*. 1996; 8(9):893–8. PMID: 8889457
83. Yamamoto-Furusho JK. Clinical Epidemiology of Ulcerative Colitis in Mexico. *J Clin Gastroenterol* [Internet]. 2009; 43(3):221–4. Available from: <http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00004836-200903000-00004> <https://doi.org/10.1097/MCG.0b013e31817a76b4> PMID: 19057395